Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 2020

View Archived Issues

Glial roles in AD not well predicted by mice

Cord blood cells improve islet transplantation outcomes

Engineered enzyme alleviates intracellular NADH:NAD+ imbalance by targeting circulating lactate

The metastasis-initiating capacity of L1 cell adhesion molecule in human colorectal cancer

Mutations in Gli3 linked to Kallmann syndrome

Development of novel peptide-TLR-7/8a conjugate vaccine platform

Proteostasis Therapeutics synthesizes new USP14 inhibitors

Pliant Therapeutics patents integrin alphavbeta6 antagonists

Tufts Medical Center divulges CDK6 inhibitors

Hepatikos Therapeutics describes new MAP3K5 inhibitors

TSRL discloses various compounds for viral infections

Oncolytic viruses increase sensitivity to checkpoint blockade

FDA clears Bridge Biotherapeutics' IND for BBT-176

Sunosi approved in E.U. for excessive daytime sleepiness in adults with narcolepsy or OSA

FDA approves Polaryx's IND for PLX-200 in LINCL

European Commission approves Mayzent for secondary progressive MS

Genes involved in T-cell regulation found tied to asthma

European approval for use of Darzalex for transplant-eligible newly diagnosed multiple myeloma

Full results reported for second phase III trial of anifrolumab in systemic lupus erythematosus

Emrok and Emrok O approved in India for acute bacterial skin and skin structure infections

E.U. approval for Polivy for relapsed/refractory DLBCL

Candidate rabies vaccine ChAdOx2 RabG begins first-in-human study

LB Pharmaceuticals begins phase I study of LB-102 for schizophrenia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...